C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)

• CAS Number:

  1966153-17-2

• UNSPSC Description:

  C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor[1][2][3].

• Target Antigen:

  Endothelin Receptor; Histamine Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling

• Field of Research:

  Metabolic Disease; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/c-type-natriuretic-peptide-cnp-1-22-human-tfa.html

• Purity:

  98.10

• Solubility:

  H2O : 2 mg/mL (ultrasonic)

• Smiles:

  C(C(O)=O)(F)(F)F.C([C@@H]1NC(=O)[C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC(CN)=O)CC(C)C)=O)CO)=O)CCCCN)=O)=O)CSSC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@]([C@H](CC)C)(NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC1=O)[H])C2=CC=CC=C2

• Molecular Weight:

  2311.62

• References & Citations:

  [1]Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24.|[2]Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680.|[3]Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported